TY - JOUR
T1 - Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis C patients
AU - Mezina, Anya
AU - Krishnan, Arunkumar
AU - Woreta, Tinsay A.
AU - Rubenstein, Kevin B.
AU - Watson, Eric
AU - Chen, Po Hung
AU - Rodriguez-Watson, Carla
N1 - Funding Information:
Supported by the National Center for Advancing Translational Sciences, No. 5KL2TR001077-05 (to Po-Hung Chen).
Publisher Copyright:
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved
PY - 2022/6/16
Y1 - 2022/6/16
N2 - BACKGROUND Liver fibrosis is a common pathway of liver injury and is a feature of most chronic liver diseases. Fibrosis progression varies markedly in patients with hepatitis C virus (HCV). Liver stiffness has been recommended as a parameter of fibrosis progression/regression in patients with HCV. AIM To investigate changes in liver stiffness measured by transient elastography (TE) in a large, racially diverse cohort of United States patients with chronic hepatitis C (CHC). METHODS We evaluated the differences in liver stiffness between patients treated with direct-acting antiviral (DAA) therapy and untreated patients. Patients had ≥ 2 TE measurements and no prior DAA exposure. We used linear regression to measure the change in liver stiffness between first and last TE in response to treatment, controlling for age, sex, race, diabetes, smoking status, human immunodeficiency virus status, baseline alanine aminotransferase, and baseline liver stiffness. Separate regression models analyzed the change in liver stiffness as measured by kPa, stratified by cirrhosis status. RESULTS Of 813 patients, 419 (52%) initiated DAA treatment. Baseline liver stiffness was 12 kPa in 127 (16%). Median time between first and last TE was 11.7 and 12.7 mo among treated and untreated patients, respectively. There was no significant change in liver stiffness observed over time in either the group initiating DAA treatment (0.016 kPa/month; CI: -0.051, 0.084) or in the untreated group (0.001 kPa/mo; CI: -0.090, 0.092), controlling for covariates. A higher baseline kPa score was independently associated with decreased liver stiffness.
AB - BACKGROUND Liver fibrosis is a common pathway of liver injury and is a feature of most chronic liver diseases. Fibrosis progression varies markedly in patients with hepatitis C virus (HCV). Liver stiffness has been recommended as a parameter of fibrosis progression/regression in patients with HCV. AIM To investigate changes in liver stiffness measured by transient elastography (TE) in a large, racially diverse cohort of United States patients with chronic hepatitis C (CHC). METHODS We evaluated the differences in liver stiffness between patients treated with direct-acting antiviral (DAA) therapy and untreated patients. Patients had ≥ 2 TE measurements and no prior DAA exposure. We used linear regression to measure the change in liver stiffness between first and last TE in response to treatment, controlling for age, sex, race, diabetes, smoking status, human immunodeficiency virus status, baseline alanine aminotransferase, and baseline liver stiffness. Separate regression models analyzed the change in liver stiffness as measured by kPa, stratified by cirrhosis status. RESULTS Of 813 patients, 419 (52%) initiated DAA treatment. Baseline liver stiffness was 12 kPa in 127 (16%). Median time between first and last TE was 11.7 and 12.7 mo among treated and untreated patients, respectively. There was no significant change in liver stiffness observed over time in either the group initiating DAA treatment (0.016 kPa/month; CI: -0.051, 0.084) or in the untreated group (0.001 kPa/mo; CI: -0.090, 0.092), controlling for covariates. A higher baseline kPa score was independently associated with decreased liver stiffness.
KW - Chronic hepatitis c
KW - Cirrhosis
KW - Direct-acting antiviral therapy
KW - Liver stiffness
KW - Transient elastography
UR - http://www.scopus.com/inward/record.url?scp=85131741551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131741551&partnerID=8YFLogxK
U2 - 10.12998/wjcc.v10.i17.5566
DO - 10.12998/wjcc.v10.i17.5566
M3 - Article
C2 - 35979107
AN - SCOPUS:85131741551
SN - 2307-8960
VL - 10
SP - 5566
EP - 5576
JO - World Journal of Clinical Cases
JF - World Journal of Clinical Cases
IS - 17
ER -